BioCentury
ARTICLE | Company News

EC conditionally approves Seattle Genetics' Adcetris

November 1, 2012 1:34 AM UTC

Seattle Genetics Inc. (NASDAQ:SGEN) and partner Millennium Pharmaceuticals Inc. said the European Commission conditionally approved an MAA for Adcetris brentuximab vedotin to treat anaplastic large cell lymphoma (ALCL) and Hodgkin's lymphoma. Specifically, Adcetris is approved for relapsed or refractory systemic ALCL and for relapsed or refractory CD30-positive Hodgkin's lymphoma following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. The approval triggers two milestone payments totaling $25 million to Seattle Genetics from Millennium, a subsidiary of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502). Takeda said it plans to launch Adcetris in Europe in "the coming weeks." ...